Navigation Links
Epizyme Receives Orphan Drug Designation for EPZ-5676
Date:8/16/2013

l exclusively enroll MLL-r patients.

Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the United States. Epizyme has partnered with Abbott to develop a companion diagnostic to identify MLL-r patients. Additional information about these partnerships may be found here: http://www.epizyme.com/about-us/partnerships.asp

About MLL-r

MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). The disease predominantly occurs in two different age ranges, an adult population and a pediatric population. Although both age ranges share a common genetic driver, the adult disease is frequently a secondary leukemia resulting from prior chemotherapy for a different, unrelated cancer, while the pediatric disease is sporadic in nature. According to research published in the journal Blood in December 2002, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. The five-year event-free survival rate in pediatric patients with the most common MLL-r subtype of ALL is approximately 27 percent, as identified in research published in the New England Journal of Medicine in 2004. The total annual incidence of MLL-r in all patients (adult and pediatric, AML and ALL) in major pharmaceutical markets is approximately 4,900 patients, according to a report by Clarion Healthcare commissioned by Epizyme. Patients with MLL-r are routinely diagnosed today with existing tests that are commonly used in clinical settings, and there is high awareness of MLL-r among oncologists.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. Epizyme to Present at Upcoming Conferences in February
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Epizyme, Inc. Announces Pricing of Initial Public Offering
6. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
7. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
8. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... Sept. 8 FluoroPharma, Inc. announced today ... Scientific Advisor,will report on two preclinical studies ... (PET) molecular imaging agents for detection,of Alzheimer,s ... World Molecular,Imaging Congress, in Nice, France on ...
... PRINCETON, N.J., Sept. 8 Medarex, Inc.,(Nasdaq: ... milestone payment for an,undisclosed amount from its licensing ... is a result of the submission of an ... clinical development of an antibody,generated by Medarex,s UltiMAb(R) ...
Cached Medicine Technology:FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 3Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 2Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 3
(Date:7/28/2014)... Philadelphia, PA (PRWEB) July 28, 2014 ... die each year from metastatic breast and prostate cancers ... when the cancer has spread to other parts of ... brain. Now researchers at Drexel University College of ... target they identified that inhibits metastatic progression by blocking ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... it takes humans just milliseconds to look at someone,s face ... new study finds that certain facial features seem to trigger ... shape and size of the mouth, for example, appear directly ... keys to attractiveness. The study findings suggest that ...
(Date:7/28/2014)... of a surgical procedure to treat severe chronic migraine ... percent of the time in patients treated at Massachusetts ... of Plastic and Reconstructive Surgery report that more than ... all of whom had headaches associated with compression ... year later. The team,s paper has received advance ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Thousands of ... on behalf of individuals who were allegedly injured by ... continue to move forward in U.S. District Court, Northern ... an Order issued on July 18, 2014, U.S. District ... filed by the Plaintiffs’ Steering Committee that sought the ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... SAN DIEGO, Sept. 14 Amylin Pharmaceuticals,Inc. (Nasdaq: ... at,an investor reception during the 43rd Annual Meeting of ... Wednesday, September 19,2007 at 4:30 a.m. PT / 1:30 ... live presentation will be webcast, and recordings will be ...
... BIRMINGHAM, Ala., Sept. 14 /PRNewswire-USNewswire/,-- ProAssurance Group ... a specialized,professional liability program designed for Michigan,s ... through Physicians Insurance Company,of Wisconsin, Inc. (PIC ... pleased to have the opportunity to serve ...
... product dissolves naturally , THURSDAY, Sept. 13 (HealthDay News) -- ... someone else,s used-up chewing gum. , But relief may be ... non -stick, easy-to-remove version of chewing gum at the BA ... be easily removed from shoes, clothes, hair and sidewalks, and ...
... Sept. 14 Michael Bond has,been named the ... following nearly 30 years in various roles for ... Blade Process,Engineering. Bond has a wealth of experience ... leading edge technologies for,IncisionTech and Specialty Blades. ...
... Stryker,Corporation (NYSE: SYK ) announced today that ... 25, 2007 - 4:30 p.m. Eastern Time UBS ... A simultaneous webcast of the Company,s presentation will ... the For Investors page. The,presentation for the UBS conference ...
... Most people looking for tax advice,usually go to an ... Here,s more on a new report that shows a ... actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, graphics ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: